Biogen Inc. (NASDAQ:BIIB) Insider Priya Singhal Sells 93 Shares

Biogen Inc. (NASDAQ:BIIBGet Free Report) insider Priya Singhal sold 93 shares of the business’s stock in a transaction on Tuesday, April 2nd. The shares were sold at an average price of $213.09, for a total transaction of $19,817.37. Following the transaction, the insider now owns 4,886 shares of the company’s stock, valued at $1,041,157.74. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Priya Singhal also recently made the following trade(s):

  • On Thursday, February 22nd, Priya Singhal sold 262 shares of Biogen stock. The shares were sold at an average price of $221.23, for a total transaction of $57,962.26.
  • On Friday, February 16th, Priya Singhal sold 108 shares of Biogen stock. The shares were sold at an average price of $221.49, for a total transaction of $23,920.92.
  • On Monday, February 12th, Priya Singhal sold 419 shares of Biogen stock. The shares were sold at an average price of $239.45, for a total transaction of $100,329.55.

Biogen Stock Performance

NASDAQ:BIIB opened at $206.38 on Thursday. The company has a debt-to-equity ratio of 0.46, a current ratio of 2.00 and a quick ratio of 1.26. The firm has a market capitalization of $30.00 billion, a price-to-earnings ratio of 25.86, a PEG ratio of 1.73 and a beta of -0.02. The company’s 50-day moving average is $226.85 and its two-hundred day moving average is $240.75. Biogen Inc. has a 1-year low of $205.36 and a 1-year high of $319.76.

Biogen (NASDAQ:BIIBGet Free Report) last posted its earnings results on Tuesday, February 13th. The biotechnology company reported $2.95 earnings per share for the quarter, missing the consensus estimate of $3.18 by ($0.23). Biogen had a net margin of 11.81% and a return on equity of 14.91%. The firm had revenue of $2.39 billion during the quarter, compared to analyst estimates of $2.47 billion. During the same quarter in the previous year, the firm earned $4.05 earnings per share. Analysts forecast that Biogen Inc. will post 15.48 EPS for the current year.

Hedge Funds Weigh In On Biogen

Large investors have recently made changes to their positions in the stock. Altshuler Shaham Ltd acquired a new position in shares of Biogen in the 4th quarter worth approximately $25,000. OFI Invest Asset Management acquired a new position in shares of Biogen in the 3rd quarter worth approximately $26,000. Livelsberger Financial Advisory acquired a new position in shares of Biogen in the 4th quarter worth approximately $26,000. Gladius Capital Management LP acquired a new position in shares of Biogen in the 3rd quarter worth approximately $28,000. Finally, KB Financial Partners LLC lifted its holdings in shares of Biogen by 105.1% in the 3rd quarter. KB Financial Partners LLC now owns 121 shares of the biotechnology company’s stock worth $31,000 after acquiring an additional 62 shares during the last quarter. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. Needham & Company LLC cut their price objective on shares of Biogen from $305.00 to $300.00 and set a “buy” rating for the company in a report on Tuesday, February 13th. Mizuho cut their price objective on shares of Biogen from $355.00 to $277.00 and set a “buy” rating for the company in a report on Thursday, February 22nd. Robert W. Baird cut their price objective on shares of Biogen from $333.00 to $316.00 and set an “outperform” rating for the company in a report on Wednesday, February 14th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $364.00 price objective on shares of Biogen in a report on Tuesday, March 5th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $311.00 price objective on shares of Biogen in a report on Tuesday, February 20th. Nine investment analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $305.68.

Check Out Our Latest Report on Biogen

Biogen Company Profile

(Get Free Report)

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.

Featured Stories

Insider Buying and Selling by Quarter for Biogen (NASDAQ:BIIB)

Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.